Product Details
| Product Name:
TAS-103 dihydrochloride |
CAS No.:
174634-09-4 |
| Purity:
97.78% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | TAS-103 dihydrochloride |
| Description | TAS-103 dihydrochloride (BMS-247615 dihydrochloride) is a novel anticancer agent targeting both topoisomerase (Topo) I and Topo II. |
| In vitro | The in vitro antitumor effects of TAS-103 were compared with those of other known Topo I and Topo II inhibitors. TAS-103 inhibited DNA synthesis more strongly than RNA and protein synthesis, and induced an increase of cell population in the S-G2/M phase. The cytotoxicity of TAS-103 was strongest against S-phase cells, but its cell cycle phase specificity was not clear, and depended on drug concentration and exposure time. The cytotoxicity of TAS-103 (IC50: 0.0030-0.23 microM) against various tumor cell lines was much stronger than that of VP-16 and comparable to that of SN-38. The cytotoxicity of TAS-103 seemed to be more related to the amount of protein-DNA complexes than to the accumulation of TAS-103 in the cells. P-Glycoprotein (P-gp)-mediated MDR, CDDP-resistant and 5-FU-resistant cell lines did not show cross-resistance to TAS-103. Although PC-7/CPT cells bearing a Topo I gene mutation showed cross-resistance to TAS-103, the sensitivity of P388/CPT, HT-29/CPT and St-4/CPT cells, showing decreased Topo I expression, was not changed. KB/VM4 and HT-29/Etp cells, showing decreased Topo II expression, were slightly cross-resistant to TAS-103. These results suggest that TAS-103 may act as an inhibitor of both Topo I and Topo II at the cellular level[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 50 mg/mL (123.06 mM), Sonication is recommended.
|
| Keywords | Topoisomerase | TAS-103 | TAS 103 | inhibit | TAS 103 dihydrochloride | TAS-103 Dihydrochloride | Inhibitor | TAS103 dihydrochloride | BMS-247615 Dihydrochloride | TAS103 Dihydrochloride | TAS103 | BMS-247615 | BMS 247615 | BMS 247615 Dihydrochloride | TAS 103 Dihydrochloride | BMS247615 | BMS247615 Dihydrochloride |
| Inhibitors Related | Berberine chloride | EIDD-1931 | Flumequine | Norfloxacin | Prulifloxacin | Enoxacin | Pefloxacin Mesylate | Camptothecin | Ciprofloxacin | Ciprofloxacin monohydrochloride | Irinotecan hydrochloride trihydrate | Etoposide |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | ReFRAME Related Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1584160-52-0
$890.00 / 5mg
-
CAS:1198221-21-4
$299.00 / 2mg
-
CAS:193620-69-8
$42.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 |
|
|
$33.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
|
|
$200.00/1KG |
VIP2Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2023-10-08 |
United States